Humana (NYSE:HUM) Stock Price Down 4.8%

Shares of Humana Inc. (NYSE:HUM) fell 4.8% during mid-day trading on Monday . The company traded as low as $338.23 and last traded at $340.61. 272,391 shares changed hands during mid-day trading, a decline of 83% from the average session volume of 1,617,979 shares. The stock had previously closed at $357.86.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on HUM shares. Bank of America lifted their price target on shares of Humana from $342.00 to $376.00 and gave the company a “neutral” rating in a research note on Monday, May 20th. Cantor Fitzgerald reissued a “neutral” rating and issued a $395.00 price objective on shares of Humana in a research report on Monday, August 19th. Truist Financial lifted their price objective on shares of Humana from $355.00 to $400.00 and gave the company a “hold” rating in a research report on Monday, July 15th. JPMorgan Chase & Co. lifted their price objective on shares of Humana from $332.00 to $396.00 and gave the company a “neutral” rating in a research report on Wednesday, August 21st. Finally, Morgan Stanley began coverage on shares of Humana in a report on Monday, June 24th. They set an “equal weight” rating and a $374.00 target price for the company. Thirteen investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $398.70.

Humana Trading Down 3.5 %

The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.66 and a current ratio of 1.66. The firm has a 50-day moving average of $367.68 and a 200-day moving average of $347.40. The firm has a market capitalization of $41.59 billion, a P/E ratio of 22.28, a price-to-earnings-growth ratio of 2.80 and a beta of 0.50.

Humana (NYSE:HUM) last posted its earnings results on Wednesday, July 31st. The insurance provider reported $6.96 EPS for the quarter, topping the consensus estimate of $5.89 by $1.07. Humana had a net margin of 1.53% and a return on equity of 16.12%. The firm had revenue of $29.54 billion during the quarter, compared to analysts’ expectations of $28.52 billion. During the same period last year, the company posted $8.94 EPS. The company’s quarterly revenue was up 10.4% compared to the same quarter last year. On average, equities research analysts anticipate that Humana Inc. will post 16 EPS for the current fiscal year.

Humana Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Monday, September 30th will be given a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a yield of 1.02%. The ex-dividend date is Monday, September 30th. Humana’s dividend payout ratio (DPR) is presently 22.04%.

Institutional Trading of Humana

Hedge funds have recently bought and sold shares of the stock. Private Wealth Management Group LLC purchased a new position in shares of Humana in the 4th quarter worth $32,000. CarsonAllaria Wealth Management Ltd. raised its stake in shares of Humana by 111.4% in the second quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock valued at $28,000 after acquiring an additional 39 shares during the period. Hantz Financial Services Inc. bought a new stake in shares of Humana in the 2nd quarter worth about $35,000. Family Firm Inc. purchased a new position in shares of Humana during the 2nd quarter worth about $37,000. Finally, Carolinas Wealth Consulting LLC raised its position in Humana by 274.1% in the 4th quarter. Carolinas Wealth Consulting LLC now owns 101 shares of the insurance provider’s stock worth $46,000 after purchasing an additional 74 shares during the period. Institutional investors own 92.38% of the company’s stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.